Q2 2018 13F Holders as of 30 Jun 2018
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
95,963,102
-
Number of holders
-
151
-
Total 13F shares, excl. options
-
48,810,187
-
Shares change
-
-64,961
-
Total reported value, excl. options
-
$3,751,960,915
-
Value change
-
+$16,214,593
-
Put/Call ratio
-
112%
-
Number of buys
-
75
-
Number of sells
-
-82
-
Price
-
$76.87
Significant Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q2 2018
185 filings reported holding RARE - Ultragenyx Pharmaceutical Inc. - COMMON STOCK as of Q2 2018.
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) has 151 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 48,810,187 shares
of 95,963,102 outstanding shares and own 51% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (6,090,143 shares), Capital Research Global Investors (5,755,563 shares), BlackRock Inc. (4,389,350 shares), VANGUARD GROUP INC (4,075,248 shares), Capital International Investors (3,604,764 shares), FMR LLC (3,459,085 shares), PRICE T ROWE ASSOCIATES INC /MD/ (2,796,392 shares), STATE STREET CORP (1,648,751 shares), FEDERATED INVESTORS INC /PA/ (1,417,551 shares), and AMERIPRISE FINANCIAL INC (1,331,462 shares).
This table shows the top 151 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.